BBIO FY 2024 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$222M+2285.3% YoY

Gross Profit

$218M98.3% margin

Operating Income

-$593M-267.2% margin

Net Income

-$536M-241.4% margin

EPS (Diluted)

$-2.88

Cash Flow

Operating Cash Flow

-$521M

Free Cash Flow

-$522M

Stock-Based Comp.

$96M

Balance Sheet

Total Assets

$919M

Total Liabilities

$2.4B

Stockholders' Equity

-$1.5B

Cash & Equivalents

$681M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$222M	$9M	+2285.3%
Gross Profit	$218M	$7M	+3079.6%
Operating Income	-$593M	-$607M	+2.4%
Net Income	-$536M	-$643M	+16.7%